AAAAI & ACAAI GUIDELINES Bundle (free trial)

Chronic Rhinosinusitis with Nasal Polyps

AAAAI & ACAAI GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512443

Contents of this Issue

Navigation

Page 5 of 7

Treatment Table 3. Biologic Agents for CRSwNP Agent Brand Name Type Indication Benralizumab FASENRA Interleukin-5 receptor alpha- directed cytolytic monoclonal antibody (IgG1, kappa) Add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype Dupilumab DUPIXENT Interleukin-4 receptor alpha antagonist Add-on maintenance treatment in adult patients with inadequately controlled CRSwNP a Mepolizumab NUCALA Interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) Add-on maintenance treatment of adult patients 18 years and older with CRSwNP b Omalizumab XOLAIR XOLAIR PFS Anti- IgE antibody Add-on maintenance in adult patients 18 years of age and older with CRSwNP c a Also indicated for atopic dermatitis, asthma, eosinophilic esophagitis and prurigo nodularis. b Also indicated for eosinophilic asthma, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. c Also indicated for moderate to severe persistent asthma and chronic spontaneous urticaria (CSU).

Articles in this issue

Archives of this issue

view archives of AAAAI & ACAAI GUIDELINES Bundle (free trial) - Chronic Rhinosinusitis with Nasal Polyps